ClinicalTrials.gg
TerminatedNCT03728933Updated Oct 26, 2023Results posted

A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause

A Phase 3 interventional study of Rotigotine 1 milligram/24 hours and Rotigotine 2 milligram/24 hours in Restless Legs Syndrome, sponsored by UCB Biopharma SRL. Terminated at 1 site in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-10-26.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor decision; Not a safety decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
13 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing rotigotine in Restless Legs Syndrome — none open to participants now, none under way, none of them phase 3. rotigotine · Restless Legs Syndrome.

Enrollment
16th of 19
23 · median 130
Started
2018
the only one that year
Phase 3
10 of 19
none open now
Registered
18th of 19
by date
Lead sponsor
2 of 19
UCB Biopharma SRL

Among the 19 studies testing rotigotine in Restless Legs Syndrome, this one is the 16th largest by enrollment, is the only one that started in 2018, is one of 10 in phase 3, and was the 18th registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

None of the 19 studies testing rotigotine in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 13 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing rotigotine in Restless Legs Syndrome as a file.
02

Study summary

The purpose of this study is to demonstrate the efficacy of rotigotine against placebo in adolescent subjects with idiopathic Restless Legs Syndrome (RLS) over a 12-week maintenance period and to investigate the safety and tolerability of rotigotine in adolescent subjects with idiopathic RLS.

03

Conditions studied

  • Restless Legs Syndrome

Keywords

  • RLS
  • Rotigotine
  • Neupro
04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is male or female, and is >=13 and \<18 years of age at Baseline
  • Subject's Restless Legs Syndrome (RLS) symptoms cause significant daytime symptoms or significant distress or impairment in social, occupational, educational, or other important areas of functioning by the impact on sleep, energy/vitality, daily activities, behavior, cognition or mood
  • At Baseline, subject has a score of >=15 on the International Restless Legs Rating Scale (IRLS) (indicating moderate-to-severe RLS)
  • At Baseline, subject scores >=4 points on the Clinical Global Impressions (CGI) Item 1 assessment (indicating at least moderately ill)
  • Subjects who are receiving supplemental iron have been on a stable dose for at least 1 month prior to Screening
  • Female subjects must be surgically incapable of childbearing, or effectively practicing an acceptable method of (oral/parenteral/implantable hormonal contraceptives, intrauterine device, or barrier and spermicide). Abstinence is an acceptable method. Subjects must agree to use adequate contraception during the study and for 4 weeks after their final dose of study medication.

Exclusion criteria

Exclusion Criteria:

  • Subject has a serum ferritin level below the lower limit of normal at Visit 1/Screening
  • Subject has a level below the lower limit of normal at Visit 1/Screening
  • Subject has had previous treatment with dopamine agonists or L-dopa within 7 days prior to Visit 2/Baseline
  • Subject has any medical or psychiatric condition, which in the opinion of the investigator, would jeopardize or compromise the subject's well-being or ability to participate in this study
  • Subject is pregnant or nursing
  • Subject is not willing to abstain from caffeine after 4 pm each evening within 7 days prior to Visit 2/Baseline and for the duration of the study
  • At Visit 1/Screening, subject has symptomatic orthostatic hypotension with a decrease of blood pressure (BP) from supine to standing position of >=20 mmHg in systolic blood pressure (SBP) or of >=10 mmHg in diastolic
  • Subject has secondary Restless Legs Syndrome (RLS) (eg, due to renal insufficiency [uremia], iron deficiency, or rheumatoid arthritis)
  • Subject has a lifetime history of suicide attempts (including actual attempt, interrupted attempt, or aborted attempt), or had suicidal ideation in the past 6 months as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening (Visit 1)
  • Subject is taking a prohibited concomitant medication. Prohibited concomitant medication must have been discontinued at least 2 weeks prior to Screening (Visit 1)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    2 milligram/24 hours rotigotine

    Subjects randomized to this arm will be initiated on 1 milligram (mg)/24 hours (h) rotigotine and up-titrated to a maximum of 2 mg/24 h rotigotine, which is the assigned dose level throughout the 12-week Maintenance Period.

    Drug: Rotigotine 1 milligram/24 hours · Drug: Rotigotine 2 milligram/24 hours

  • Experimental
    3 milligram/24 hours rotigotine

    Subjects randomized to this arm will be initiated on 1 milligram (mg)/24 hours (h) rotigotine and up-titrated to a maximum of 3 mg/24 h rotigotine (1 mg/24 h patch + 2 mg/24 patch at the same time), which is the assigned dose level throughout the 12-week Maintenance Period.

    Drug: Rotigotine 1 milligram/24 hours · Drug: Rotigotine 2 milligram/24 hours

  • Placebo comparator
    Placebo

    Subjects randomized to this arm will receive matching placebo patches to maintain the blinding.

    Drug: Placebo

Interventions

  • DrugRotigotine 1 milligram/24 hours

    Drug page: Rotigotine

    Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 1 milligram (mg)/24 hours (h) (5 square centimeter (cm\^2) patch size).

    Also known as: Neupro

  • DrugRotigotine 2 milligram/24 hours

    Drug page: Rotigotine

    Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 2 milligram (mg)/24 hours (h) (10 square centimeter (cm\^2) patch size).

    Also known as: Neupro

  • DrugPlacebo

    Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: not applicable

06

What researchers measure

Primary outcomes

  1. Change From Baseline to the End of the Maintenance Period in International Restless Legs Rating Scale (IRLS) Sum Score

    The IRLS consisted of 10 questions, each scored using a 5-point scale ranging from 0=not present to 4=very severe. The IRLS sum score was calculated by summing up the single scores of all applicable questions, i.e., the total sum score ranged from 0 (no RLS symptoms present) to 40 (maximum severity in all symptoms). A score between 31 and 40, indicates very severe RLS. A score between 21 and 30 indicates severe RLS. A score between 11 and 20 indicates moderate RLS. A score between 1 and 10 indicates mild RLS and a score of 0 means no RLS. A negative change from Baseline indicates improvement.

    Time frame: From Baseline to the end of the Maintenance Period (Day 106)

  2. Change From Baseline in Clinical Global Impressions (CGI) Item 1 to the End of the Maintenance Period

    The Clinical Global Impressions Item 1 (Severity of Illness) score ranges from 0 to 7 as follows: 0=not assessed, 1=normal, not ill at all, 2=borderline ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill. The CGI Item 1 was completed during an interview between the participant and the investigator or designee. A negative change from Baseline indicates improvement.

    Time frame: From Baseline to the end of the Maintenance Period (Day 106)

  3. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    TEAEs were defined as events that started during the Treatment Period or within 30 days following the end of the Treatment Period (i.e., on or after the date of first patch application and within 30 days following the date of last patch removal + 1 day), or those events where the intensity worsened within this time frame.

    Time frame: From Baseline to Safety Follow-Up (up to Week 20)

  4. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawals

    TEAEs were defined as events that started during the Treatment Period or within 30 days following the end of the Treatment Period (i.e., on or after the date of first patch application and within 30 days following the date of last patch removal + 1 day), or those events where the intensity worsened within this time frame.

    Time frame: From Baseline to Safety Follow-Up (up to Week 20)

Secondary outcomes

  1. Change From Baseline in Restless Legs-6 Rating Scales (RLS-6) to the End of the Maintenance Period

    The RLS-6 Rating Scales was designed to assess the severity of RLS and consisted of 6 subscales. The subscales assessed severity of symptoms at the following times of the day/evening: falling asleep, during the night, during the day at rest, and during the day when engaged in daytime activities. In addition, the subscales assessed satisfaction with sleep and severity of daytime tiredness/sleepiness. Scores for each of the 6 subscales ranged from 0 (completely satisfied) to 10 (completely dissatisfied). The change from baseline was derived for each of the subscales and reported in this outcome measure. A negative change from Baseline indicates improvement.

    Time frame: From Baseline to the end of the Maintenance Period (Day 106)

07

Results

Posted Oct 26, 2023

Participant flow

The study started to enroll participants in December 2018 and concluded prematurely in July 2022.

Participant flow — Overall Study
MilestonePlaceboRotigotine 2 mg/24hRotigotine 3 mg/24h
Started887
Completed576
Not completed311
Withdrew: Withdrawal by parent/guardian200
Withdrew: Withdrawal by subject001
Withdrew: Lost to follow-up010
Withdrew: Adverse event100

Outcome measures

PrimaryChange From Baseline to the End of the Maintenance Period in International Restless Legs Rating Scale (IRLS) Sum Score

The IRLS consisted of 10 questions, each scored using a 5-point scale ranging from 0=not present to 4=very severe. The IRLS sum score was calculated by summing up the single scores of all applicable questions, i.e., the total sum score ranged from 0 (no RLS symptoms present) to 40 (maximum severity in all symptoms). A score between 31 and 40, indicates very severe RLS. A score between 21 and 30 indicates severe RLS. A score between 11 and 20 indicates moderate RLS. A score between 1 and 10 indicates mild RLS and a score of 0 means no RLS. A negative change from Baseline indicates improvement.

Time frame:
From Baseline to the end of the Maintenance Period (Day 106)
Reported as:
Mean · score on a scale
Change From Baseline to the End of the Maintenance Period in International Restless Legs Rating Scale (IRLS) Sum Score
score on a scalePlaceboRotigotine 2 mg/24hRotigotine 3 mg/24h
Change From Baseline to the End of the Maintenance Period in International Restless Legs Rating Scale (IRLS) Sum Score-8.2 ± 6.8-14.0 ± 8.2-6.4 ± 5.8
PrimaryChange From Baseline in Clinical Global Impressions (CGI) Item 1 to the End of the Maintenance Period

The Clinical Global Impressions Item 1 (Severity of Illness) score ranges from 0 to 7 as follows: 0=not assessed, 1=normal, not ill at all, 2=borderline ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill. The CGI Item 1 was completed during an interview between the participant and the investigator or designee. A negative change from Baseline indicates improvement.

Time frame:
From Baseline to the end of the Maintenance Period (Day 106)
Reported as:
Mean · score on a scale
Change From Baseline in Clinical Global Impressions (CGI) Item 1 to the End of the Maintenance Period
score on a scalePlaceboRotigotine 2 mg/24hRotigotine 3 mg/24h
Change From Baseline in Clinical Global Impressions (CGI) Item 1 to the End of the Maintenance Period-1.0 ± 1.4-1.7 ± 1.1-0.8 ± 0.8
PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs)

TEAEs were defined as events that started during the Treatment Period or within 30 days following the end of the Treatment Period (i.e., on or after the date of first patch application and within 30 days following the date of last patch removal + 1 day), or those events where the intensity worsened within this time frame.

Time frame:
From Baseline to Safety Follow-Up (up to Week 20)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
percentage of participantsPlaceboRotigotine 2 mg/24hRotigotine 3 mg/24h
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)87.587.571.4
PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawals

TEAEs were defined as events that started during the Treatment Period or within 30 days following the end of the Treatment Period (i.e., on or after the date of first patch application and within 30 days following the date of last patch removal + 1 day), or those events where the intensity worsened within this time frame.

Time frame:
From Baseline to Safety Follow-Up (up to Week 20)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawals
percentage of participantsPlaceboRotigotine 2 mg/24hRotigotine 3 mg/24h
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawals12.500
SecondaryChange From Baseline in Restless Legs-6 Rating Scales (RLS-6) to the End of the Maintenance Period

The RLS-6 Rating Scales was designed to assess the severity of RLS and consisted of 6 subscales. The subscales assessed severity of symptoms at the following times of the day/evening: falling asleep, during the night, during the day at rest, and during the day when engaged in daytime activities. In addition, the subscales assessed satisfaction with sleep and severity of daytime tiredness/sleepiness. Scores for each of the 6 subscales ranged from 0 (completely satisfied) to 10 (completely dissatisfied). The change from baseline was derived for each of the subscales and reported in this outcome measure. A negative change from Baseline indicates improvement.

Time frame:
From Baseline to the end of the Maintenance Period (Day 106)
Reported as:
Mean · score on a scale
Change From Baseline in Restless Legs-6 Rating Scales (RLS-6) to the End of the Maintenance Period
score on a scalePlaceboRotigotine 2 mg/24hRotigotine 3 mg/24h
Satisfaction with sleep-1.8 ± 4.1-4.7 ± 2.3-2.0 ± 2.8
Severity: RLS symptoms at falling asleep-2.8 ± 3.6-5.6 ± 1.6-2.8 ± 1.8
Severity: RLS symptoms during the night-1.0 ± 2.5-2.9 ± 3.0-2.4 ± 2.2
Severity: RLS symptoms during the day - at rest-1.4 ± 1.3-3.6 ± 3.5-2.4 ± 2.6
Severity: RLS symptoms during the day-not at rest-3.8 ± 1.9-4.3 ± 3.5-0.4 ± 1.1
How tired or sleepy during the day-3.0 ± 2.8-5.6 ± 2.1-3.0 ± 1.9

Adverse events

Collected over From Baseline to Safety Follow-Up (up to Week 20). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/8 (0%)0/8 (0%)7/8 (87.5%)
Rotigotine 2 mg/24h0/8 (0%)0/8 (0%)7/8 (87.5%)
Rotigotine 3 mg/24h0/7 (0%)1/7 (14.3%)5/7 (71.4%)
Most frequent serious events
Most frequent serious events
EventPlaceboRotigotine 2 mg/24hRotigotine 3 mg/24h
Type 2 diabetes mellitusMetabolism and nutrition disorders0/80/81/7
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPlaceboRotigotine 2 mg/24hRotigotine 3 mg/24h
Application site erythemaGeneral disorders1/84/81/7
Upper respiratory tract infectionInfections and infestations1/80/83/7
Application site pruritusGeneral disorders0/83/81/7
NauseaGastrointestinal disorders1/82/80/7
VomitingGastrointestinal disorders1/82/80/7
Abdominal painGastrointestinal disorders2/80/80/7
NasopharyngitisInfections and infestations2/80/80/7
DizzinessNervous system disorders2/80/81/7
PruritusSkin and subcutaneous tissue disorders0/82/81/7
Skin irritationSkin and subcutaneous tissue disorders0/82/80/7

Baseline characteristics

The Randomized Set consisted of all participants from the Enrolled Set who have been randomized.

Age, Continuous
Age, Continuous(years)PlaceboRotigotine 2 mg/24hRotigotine 3 mg/24hTotal
Mean15.4 ± 1.316.1 ± 1.115.6 ± 1.015.7 ± 1.1
Age, Customized
Age, Customized(Participants)PlaceboRotigotine 2 mg/24hRotigotine 3 mg/24hTotal
Adolescents (12-17 years)88723
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRotigotine 2 mg/24hRotigotine 3 mg/24hTotal
Female66214
Male2259
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRotigotine 2 mg/24hRotigotine 3 mg/24hTotal
American Indian/Alaskan Native0101
Black0011
White77620
Other/Mixed1001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRotigotine 2 mg/24hRotigotine 3 mg/24hTotal
Not Hispanic or Latino88723
08

Study locations

1 site
  • Sp1006 101
    Culver City, California 90230, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Jul 2022, 43 months.

Results were first posted in Oct 2023, 1 year 3 months after primary completion. A results delay was requested in Jul 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2018
First posted
Nov 2, 2018
StartActual
Dec 20, 2018
Primary completionActual
Jul 25, 2022
CompletionActual
Jul 25, 2022
Results delay requested
Jul 21, 2023
Results first posted
Oct 26, 2023
Last update
Oct 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03728933
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Nov 2, 2018
Start date
Dec 20, 2018
Primary completion
Jul 25, 2022
Completion
Jul 25, 2022
Results posted
Oct 26, 2023
Last update
Oct 26, 2023

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion